Updated 2026 International EAACI Guideline1: RHAPSIDO included in treatment algorithm-4 months post approval. |
RHAPSIDO: a first-of-its-kind* oral targeted therapy for CSU2
When antihistamines aren't enough for chronic spontaneous urticaria (CSU), cut to RHAPSIDO. It is not indicated for other forms of urticaria2
*Bruton's tyrosine kinase inhibitor indicated for CSU.2
†Multiple imputation techniques were implemented for missing data.2
‡Limitations apply. Subject to annual co-pay benefit limit. Offer not valid under Medicare, Medicaid, or any other federal or state programs. Novartis reserves the right to rescind, revoke, or amend this program without notice. Additional limitations may apply. See complete Terms & Conditions at rhapsido.com for details.
†Multiple imputation techniques were implemented for missing data.2
‡Limitations apply. Subject to annual co-pay benefit limit. Offer not valid under Medicare, Medicaid, or any other federal or state programs. Novartis reserves the right to rescind, revoke, or amend this program without notice. Additional limitations may apply. See complete Terms & Conditions at rhapsido.com for details.